BioCryst Pharmaceuticals, Inc. provided earnings guidance for the year 2024. For the year, ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales. The Company expects operating profit in 2024, approaching positive EPS.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.16 USD | 0.00% | -6.09% | -30.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.55% | 858M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024